GSK Plans Phase 3 Trial for mRNA Flu Vaccine Candidate

MT newswire2026/09/01 07:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:35 AM EDT, 09/01/2026 (MT Newswires) -- GSK (GSK) plans to advance its mRNA seasonal influenza vaccine candidate to a phase 3 efficacy trial after the vaccine showed higher immune responses in a clinical study than licensed standard dose and high dose flu vaccines, the company said Tuesday. GSK said it plans to begin the phase 3 trial in September. The vaccine is designed to target both haemagglutinin and neuraminidase, two surface antigens involved in influenza virus binding and spread, it said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41